Helicobacter pylori gastritis
Conditions
Interventions
Vonoprazan (VPZ) 20mg, Amoxicillin (ABPC) 750mg, Clarithromycin (CAM) 200mg, for the first 7days, with all drugs given twice daily
VPZ 20mg, ABPC 750mg, CAM 400mg, for the first 7days, with all drugs
Sponsors
Takamatsu Red Cross Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who received a diagnosis of Helicobacter pylori gastritis by any one method of a rapid urease test, a urea breath test, a blood antibody test, a stool antigen test, and microbial culture.
Exclusion criteria
Exclusion criteria: 1. Patients who have histories of eradication therapy for Helicobacter pylori. 2. Patients who received any one of lansoprazole, esomeprazole, omeprazole, and vonoprazan within 2 weeks. 3. Patients who suggested or received a diagnosis of other infectious diseases. 4. Patients being treated for acute gastritis, advanced gastric cancer, and gastric MALT lymphoma. 5. Patients after gastrectomy. 6. Patients who have coexisting severe heart disease, liver disease, respiratory disease, metabolic disease, neuromuscular disease, and severe chronic renal failure (estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2). 7. Patients who have a past history of allergy for vonoprazan, esomeprazole, amoxicillin, and clarithromycin. 8. Pregnancy or lactating women. 9. Patients requiring hospitalization..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate of the first-line therapy assessed by a urea breath test from 8 to 12 weeks after cessation of therapy. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects of clarithromycin resistance, eGFR, alcohol consumption, and smoking on the eradication rate of each group, and the incidence and severity of adverse events | — |
Countries
Japan
Contacts
Public ContactHiroyuki Tamaki
Takamatsu Red Cross Hospital Department of gastroenterology
Outcome results
None listed